

**Manuscript no. HAEMATOL/2012/071092 entitled “Phase 1 study of anti-CD33 immunotoxin HUM-195/rGEL in patients with advanced myeloid malignancies”**

**Authors: Gautam Borthakur, Michael G. Rosenblum, Moshe Talpaz, Naval Daver, Farhad Ravandi, Stefan Faderl, Emil J Freireich, Tapan Kadia, Guillermo Garcia-Manero, Hagop Kantarjian, Jorge E. Cortes**

**Information about the contributions of each person named as having participated in the study**

**1) Guarantor(s), i.e., person(s) who is (are) responsible for the integrity of the work as a whole:**

- Jorge Cortes, MD Anderson Cancer Center, [jcortes@mdanderson.org](mailto:jcortes@mdanderson.org)
- Gautam Borthakur, MD Anderson Cancer Center, [gborthak@mdanderson.org](mailto:gborthak@mdanderson.org)
- Moshe Talpaz, MD, The University of Michigan Hospital and Health Systems, [mtalpaz@med.umich.edu](mailto:mtalpaz@med.umich.edu)

According to the International Committee of Medical Journal Editors (ICMJE) ([http://www.icmje.org/ethical\\_1author.html](http://www.icmje.org/ethical_1author.html)): “Authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3 ..... Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship”.

The guarantors of this manuscript confirm that all persons designated as authors qualify for authorship, and that each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content.

**2) Authors who participated in the conception of the study:**

- Jorge Cortes, MD Anderson Cancer Center, [jcortes@mdanderson.org](mailto:jcortes@mdanderson.org)
- Michael G. Rosenblum, MD Anderson Cancer Center, [mrosenbl@mdanderson.org](mailto:mrosenbl@mdanderson.org)
- Hagop Kantarjian, MD Anderson Cancer Center, [hkantarjian@mdanderson.org](mailto:hkantarjian@mdanderson.org)
- Moshe Talpaz, MD, The University of Michigan Hospital and Health Systems, [mtalpaz@med.umich.edu](mailto:mtalpaz@med.umich.edu)

**3) Design & Methods. The following authors were responsible for specific investigations:**

- Jorge Cortes was responsible for designing the study, conducting the study, collecting data, consenting and treating patients, regulatory aspects of the protocol (PI of the protocol)
- Michael G. Rosenblum was responsible for overall initial design of the Phase 1 study, pharmacokinetic analysis and analysis of antigenicity
- Emil J Freireich contributed pre-clinical data and contributed to the conception of the study, [efreirei@mdanderson.org](mailto:efreirei@mdanderson.org)
- Hagop Kantarjian, Tapan Kadia, Stefan Faderl, Gautam Borthakur, Naval Daver and Farhad Ravandi contributed, consented, and treated patients
- Moshe Talpaz, [mtalpaz@med.umich.edu](mailto:mtalpaz@med.umich.edu), contributed to design of the protocol
- Guillermo Garcia-Manero for contribution of patients, [ggarciam@mdanderson.org](mailto:ggarciam@mdanderson.org)

**4) Results. The following authors were responsible for specific portions of the results, including figures and tables:**

- Jorge Cortes was responsible for treating patients, overall data collection and analysis, and for data presented in tables 1, 2 and 3.
- Michael G. Rosenblum was responsible for Figure 1
- Hagop Kantarjian for review of data and treatment of patients

- Guillermo Garcia-Manero, Review of data [ggarciam@mdanderson.org](mailto:ggarciam@mdanderson.org)
- Gautam Borthakur was compiling and analysis of results, preparing tables
- Stefan Faderl, reviewed data, [sfaderl@mdanderson.org](mailto:sfaderl@mdanderson.org)
- Farhad Ravandi, reviewed data, [fravandi@mdanderson.org](mailto:fravandi@mdanderson.org)
- Tapan Kadia reviewed data. [tkadia@mdanderson.org](mailto:tkadia@mdanderson.org)
- Naval Daver reviewed data. [NDaver@mdanderson.org](mailto:NDaver@mdanderson.org)

**5) Writing the manuscript. The following authors were responsible for writing the manuscript:**

- Jorge Cortes wrote edited and reviewed the manuscript and approved the final version.
- Hagop Kantarjian reviewed and approved final version
- Gautam Borthakur writing and approval of final version
- Stefan Faderl, reviewed and approved final version of manuscript
- Farhad Ravandi reviewed and approved final version of manuscript
- Moshe Talpaz, MD was responsible for review and correction of the manuscript
- Tapan Kadia reviewed and approved final version of manuscript
- Naval G Daver reviewed and approved final version of the manuscript
- Guillermo-Garcia Manero reviewed and approved final version of the manuscript
- Emil Freireich reviewed and approved final version of the manuscript
- Michael Rosenblum reviewed and approved final version of the manuscript, wrote correlative studies portion of the manuscript

**6) Contributors Listed in Acknowledgments:**

"This research is supported in part by the MD Anderson Cancer Center Support Grant CA016672 and the MD Anderson AML P01 Grant P01 CA0556164."